Healthcare provider profile · identity verified

Shereen Mohis, M.D.

Family Practice · OAK CREEK, WI · NPI 1043264609

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	336	96
Lisinopril	Lisinopril	302	79
Metformin Hcl	Metformin Hcl	295	76
Levothyroxine Sodium	Levothyroxine Sodium	267	69
Losartan Potassium	Losartan Potassium	230	66
Topiramate	Topiramate	229	51
Amlodipine Besylate	Amlodipine Besylate	224	70
Omeprazole	Omeprazole	218	51
Pravastatin Sodium	Pravastatin Sodium	207	53
Metoprolol Succinate	Metoprolol Succinate	196	60
Simvastatin	Simvastatin	165	53
Hydrochlorothiazide	Hydrochlorothiazide	144	36
Gabapentin	Gabapentin	139	34
Furosemide	Furosemide	113	35
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	106	27
Trazodone Hcl	Trazodone Hcl	104	26
Diclofenac Sodium	Diclofenac Sodium	103	33
Warfarin Sodium	Warfarin Sodium	97	25
Pantoprazole Sodium	Pantoprazole Sodium	95	28
Potassium Chloride	Potassium Chloride	94	33
Rosuvastatin Calcium	Rosuvastatin Calcium	91	30
Escitalopram Oxalate	Escitalopram Oxalate	90	25
Quetiapine Fumarate	Quetiapine Fumarate	90	15
Baclofen	Baclofen	89	39
Hydralazine Hcl	Hydralazine Hcl	88	31
Atenolol	Atenolol	87	22
Albuterol Sulfate Hfa	Albuterol Sulfate	85	35
Ozempic	Semaglutide	85	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	80	18
Eliquis	Apixaban	74	12
Metoprolol Tartrate	Metoprolol Tartrate	74	21
Pregabalin	Pregabalin	72	15
Clonazepam	Clonazepam	70	15
Alendronate Sodium	Alendronate Sodium	65	21
Famotidine	Famotidine	65	20
Tamsulosin Hcl	Tamsulosin Hcl	63	19
Tizanidine Hcl	Tizanidine Hcl	63	19
Clopidogrel	Clopidogrel Bisulfate	62	16
Fenofibrate	Fenofibrate Nanocrystallized	62	23
Venlafaxine Hcl Er	Venlafaxine Hcl	60	12
Fluticasone Propionate	Fluticasone Propionate	58	24
Fluoxetine Hcl	Fluoxetine Hcl	57	15
Fenofibrate	Fenofibrate	56	19
Sertraline Hcl	Sertraline Hcl	51	15
Montelukast Sodium	Montelukast Sodium	47	12
Glimepiride	Glimepiride	44	15
Meloxicam	Meloxicam	44	19
Hydroxyzine Hcl	Hydroxyzine Hcl	43	20
Allopurinol	Allopurinol	42	16
Donepezil Hcl	Donepezil Hcl	42	12
Oxybutynin Chloride Er	Oxybutynin Chloride	42	12
Bupropion Xl	Bupropion Hcl	41	13
Metformin Hcl Er	Metformin Hcl	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Jardiance	Empagliflozin	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Memantine Hcl Er	Memantine Hcl	31	suppressed
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Celecoxib	Celecoxib	30	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Linzess	Linaclotide	25	suppressed
Metolazone	Metolazone	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Alprazolam	Alprazolam	23	14
Carvedilol	Carvedilol	23	suppressed
Aripiprazole	Aripiprazole	22	suppressed
Lidocaine	Lidocaine	21	12
Propranolol Hcl	Propranolol Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Hydrocortisone	Hydrocortisone	20	12
Klor-Con M20	Potassium Chloride	20	suppressed
Mounjaro	Tirzepatide	20	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Divalproex Sodium Er	Divalproex Sodium	17	suppressed
Primidone	Primidone	17	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Glipizide	Glipizide	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Trulicity	Dulaglutide	15	suppressed
Ammonium Lactate	Ammonium Lactate	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Nystatin	Nystatin	13	suppressed
Rivastigmine	Rivastigmine	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Valsartan	Valsartan	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	12	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Niacin Er	Niacin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error